Biomarkers That Predict Response to High-Dose Aldesleukin in Patients With Metastatic Kidney Cancer or Metastatic Melanoma - Related Studies

Biomarkers That Predict Response to High-Dose Aldesleukin in Patients With Metastatic Kidney Cancer or Metastatic Melanoma

This study is currently recruiting participants.

Study NCT00617799. Last updated on October 8, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Kidney Cancer
		Melanoma (Skin)

2	Additional conditions recognized in this trial
		Carcinoma, Renal Cell
		Kidney Neoplasms
		Melanoma

3	More general conditions related to this trial
		Adenocarcinoma
		Carcinoma
		Kidney Diseases
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Germ Cell and Embryonal
		Neoplasms, Glandular and Epithelial
		Neoplasms, Nerve Tissue
		Neuroectodermal Tumors
		Neuroendocrine Tumors
		Nevi and Melanomas
		Urogenital Neoplasms
		Urologic Diseases
		Urologic Neoplasms

4	Interventions listed in this trial
		aldesleukin
		flow cytometry
		gene expression analysis
		mutation analysis

5	More general drug interventions related to this trial
		Anti-HIV Agents
		Anti-Infective Agents
		Anti-Retroviral Agents
		Antineoplastic Agents
		Antiviral Agents
		Pharmacologic Actions
		Therapeutic Uses

6	Sponsors listed in this trial
		University of Nebraska
		National Cancer Institute (NCI)